Breyanzi is a medicine used in adults to treat different types of lymphoma (cancer of white blood cells): - diffuse large B-cell lymphoma (DLBCL); - high-grade B-cell lymphoma (HGBCL); - primary mediastinal large B-cell lymphoma (PMBCL); - follicular lymphoma (FL); - mantle cell lymphoma (MCL). Breyanzi is used in adults with DLBCL, HGBCL, PMBCL and FL grade 3B (FL3B; a more aggressive form of FL) whose cancer came back (relapsed) within 12 months of finishing chemoimmunotherapy, or who did not respond (refractory) to their first round of chemoimmunotherapy. Chemoimmunotherapy is a combination of systemic therapy (treatment given by mouth or injection) to kill or slow the growth of cancer cells and immunotherapy to stimulate or restore the immune system’s ability to fight the cancer. In adults with relapsed or refractory DLBCL, PMBCL, FL3B or FL, Breyanzi can also be used after two or more previous treatments with systemic therapy. In adults with MCL, Breyanzi is used in patients whose cancer has come back or who did not respond after at least two systemic therapies including a Bruton’s tyrosine kinase inhibitor, a type of cancer medicine. Breyanzi contains lisocabtagene maraleucel, which is a combination of two types of genetically modified white blood cells.
Therapeutic Indication
### Therapeutic indication Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. Breyanzi is indicated for the treatment of adult patients with relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy. Breyanzi is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Breyanzi is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.
Therapeutic Area (MeSH)
ATC Code
L01XL08
ATC Item
lisocabtagene maraleucel
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| lisocabtagene maraleucel | N/A | Lisocabtagene maraleucel |
| CD19-directed genetically modified autologous cell-based product consisting of purified CD8+ T-cells (CD8+ cells) | N/A | cd 19-directed genetically modified autologous cell-based product consisting of purified cd 8+ t-cells (cd 8+ cells) |
| CD19-directed genetically modified autologous cell-based product consisting of purified CD4+ T cells (CD4+ cells) | N/A | cd 19-directed genetically modified autologous cell-based product consisting of purified cd 4+ t cells (cd 4+ cells) |
EMA Name
Breyanzi
Medicine Name
Breyanzi
Aliases
N/A
